NeoPhore Closes £15.2M Series B Funding Round

10 Mar, 2021

NeoPhore Closes £15.2M Series B Funding Round
Photo by Asaf Gazit on Unsplash

– NeoPhore is a Cambridge, UK-based small molecule neoantigen immuno-oncology company.
– Series B funding round closed.
– The round was led by Claris Ventures with participation from 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund.
– The new investment will be used to advance the company’s drug discovery pipeline.

Biotechnology Europe Simulation Therapeutics Translation Service
Crunchbase icon

Content report

The following text will be sent to our editors: